BP Stenabolic 10 (SR9009) is an agonist of the Rev-ErbA protein. This protein can be found in various parts of the body, including the liver and the skeletomuscular system. Studies have demonstrated it’s effects on regulating circadian rhythms, acting on fat-storing cells, and influencing lipid and glucose metabolism in the liver. Although SR9009 is not a selective androgen receptor modulator (SARM), it binds to Rev-ErBA and results in many similar effects as well as others.
SR9009 was developed in 2013 at The Scripps Research Institute (now known as Scripps Research). Early on, SR9009 was found to be highly effective in increasing the metabolic activity and skeletal muscle growth in treated mice. It does not affect endogenous testosterone levels. SR9009 is considered by many researchers to be the best SARM for cutting bodyfat.
The recommended dosage of SR9009 is 20-30mg per day, divided into two or three doses. Higher doses may be necessary for athletes or people with a high level of body fat. As with any supplement, it is important to start with a low dose and increase gradually as needed.
SR9009 has demonstrated a variety of effects in test subjects such as:
- Increased resting metabolic rate
- Regulation of circadian rhythm and sleep patterns
- Enhanced endurance
- Weight loss
- Lowered cholesterol levels
- Lowered bodily inflammation
- Arterial Plaque management
SR9009 has shown potential in the treatment of conditions such as heart failure, COPD (chronic obstructive pulmonary disease), and metabolic syndrome.
SR9009 may one day gain widespread acceptance as “exercise in a bottle.” Nevertheless, SR9009 has yet to be officially approved by the Food and Drug Administration (FDA) for human usage. Therefore, it should be considered for laboratory research purposes only at the present time, not as a complement to aerobic exercise.
More research needs to be done on human subjects. Studies performed on animals have shown that SR9009 holds promise as a health-enhancing product:
- A 2012 study found that synthetic REV-ERB agonists (like Stenabolic) altered circadian patterns in the liver, adipose tissue, and skeletal muscles of mice, boosting energy expenditure .
- A 2013 study found that mice given SR9009 could run longer distances and for longer durations than normal mice .